CANDEL THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CANDEL THERAPEUTICS, INC. (CADL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.01M, a 74.93% increase year-over-year.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.58M, a 97.87% increase year-over-year.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $1.21M, a 25.99% increase year-over-year.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.16M, a 8.10% increase year-over-year.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.32M, a 3.48% increase from fiscal 2024.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $4.17M, a 32.93% increase from fiscal 2023.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.14M, a 0.25% decline from fiscal 2022.
- CANDEL THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.15M, a 21.52% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-08-13 | $3.59M 10-Q · filed 2026-08-13 | $4.80M derived: sum of 3 quarters · filed 2026-08-13 | $5.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.58M 10-Q · filed 2026-05-14 | $2.79M derived: sum of 2 quarters · filed 2026-05-14 | $3.95M derived: sum of 3 quarters · filed 2026-05-14 | $5.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.37M derived: sum of 2 quarters · filed 2026-03-12 | $3.52M derived: sum of 3 quarters · filed 2026-08-13 | $4.32M 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.16M 10-Q · filed 2025-11-13 | $2.31M derived: sum of 2 quarters · filed 2026-08-13 | $3.11M 10-Q · filed 2025-11-13 | $4.07M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.15M 10-Q · filed 2026-08-13 | $1.95M 10-Q · filed 2026-08-13 | $2.90M derived: sum of 3 quarters · filed 2026-08-13 | $3.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $798.00K 10-Q · filed 2026-05-14 | $1.76M derived: sum of 2 quarters · filed 2026-05-14 | $2.83M derived: sum of 3 quarters · filed 2026-05-14 | $3.94M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $958.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.03M derived: sum of 2 quarters · filed 2026-03-12 | $3.14M derived: sum of 3 quarters · filed 2026-03-12 | $4.17M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.07M 10-Q · filed 2025-11-13 | $2.18M derived: sum of 2 quarters · filed 2025-11-13 | $3.21M 10-Q · filed 2025-11-13 | $4.07M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.11M 10-Q · filed 2025-08-14 | $2.14M 10-Q · filed 2025-08-14 | $3.00M derived: sum of 3 quarters · filed 2025-08-14 | $3.73M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.03M 10-Q · filed 2025-05-13 | $1.89M derived: sum of 2 quarters · filed 2025-05-13 | $2.62M derived: sum of 3 quarters · filed 2025-05-13 | $3.37M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $859.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.59M derived: sum of 2 quarters · filed 2025-03-13 | $2.34M derived: sum of 3 quarters · filed 2025-03-13 | $3.14M 10-K · filed 2025-03-13 |
| 2023-09-30 | $735.00K 10-Q · filed 2024-11-14 | $1.48M derived: sum of 2 quarters · filed 2024-11-14 | $2.28M 10-Q · filed 2023-11-09 | $3.12M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $746.00K 10-Q · filed 2024-08-13 | $1.54M 10-Q · filed 2023-08-10 | $2.38M derived: sum of 3 quarters · filed 2024-08-13 | $3.14M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $798.00K 10-Q · filed 2024-05-14 | $1.63M derived: sum of 2 quarters · filed 2024-05-14 | $2.39M derived: sum of 3 quarters · filed 2024-05-14 | $3.12M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $836.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.59M derived: sum of 2 quarters · filed 2024-03-28 | $2.32M derived: sum of 3 quarters · filed 2024-03-28 | $3.15M 10-K · filed 2024-03-28 |
| 2022-09-30 | $757.00K 10-Q · filed 2023-11-09 | $1.48M derived: sum of 2 quarters · filed 2023-11-09 | $2.31M 10-Q · filed 2023-11-09 | $2.33M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $724.00K 10-Q · filed 2023-08-10 | $1.55M 10-Q · filed 2023-08-10 | $1.58M derived: sum of 3 quarters · filed 2023-08-10 | $2.89M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $828.00K 10-Q · filed 2023-05-11 | $852.00K derived: sum of 2 quarters · filed 2023-05-11 | $2.17M derived: sum of 3 quarters · filed 2023-05-11 | $2.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.34M derived: sum of 2 quarters · filed 2023-03-30 | $2.16M derived: sum of 3 quarters · filed 2023-03-30 | $2.59M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.31M 10-Q · filed 2022-11-10 | $2.13M derived: sum of 2 quarters · filed 2022-11-10 | $2.56M 10-Q · filed 2022-11-10 | $3.84M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $819.00K 10-Q · filed 2022-08-05 | $1.25M 10-Q · filed 2022-08-05 | $2.53M derived: sum of 3 quarters · filed 2022-08-05 | $2.61M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $431.00K 10-Q · filed 2022-05-12 | $1.71M derived: sum of 2 quarters · filed 2022-05-12 | $1.79M derived: sum of 3 quarters · filed 2022-05-12 | $1.88M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.36M derived: sum of 2 quarters · filed 2022-03-29 | $1.44M derived: sum of 3 quarters · filed 2022-03-29 | $1.41M 10-K · filed 2022-03-29 |
| 2020-09-30 | $83.00K 10-Q · filed 2021-11-12 | $166.00K derived: sum of 2 quarters · filed 2021-11-12 | $134.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $83.00K 10-Q · filed 2021-09-08 | $51.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |